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Abstract 
           The two important genes of CYP450 are CYP3A4 and CYP3A5 that 
play a central role in drugs and hormones metabolisms that have a role in the 
etiology of cancers. Single nucleotide polymorphism (SNP) in these genes 
may increase the risk of developing cancers.  Numerous functional SNPs of 
the CYP3A5 gene have been connected in cancer risk, but individually 
published investigation have exposed questionable consequences. The aim of 
the current investigation and meta-analysis was to examine the link between 
polymorphism CYP3A5*3 6986 A>G [rs776746] under the heterozygous 
model and an association with increased risk of cancer. Following the 
inclusion criteria, eight studies were incorporated and 42 studies were 
excluded in this metaanalysis. The numbers of cancer cases and healthy 
controls were 4959 and 5176, respectively.  The heterogenecity model was 
significant in subgroup analysis of  Chinese, Indian, Japanese and Asian 
population suffered in TB, CML, and breast cancers [OR: 0.50, 95 %CI: 
0.30-0.81, P<0.01; OR= 1.57, 95 %CI: 1.00-2.47, P<0.05; OR=0.69; 
95%CI=0.51-0.93; P<0.01; OR=0.61; 95%CI=0.42-0.89; P<0.01]. The 
overall statistics under heterozygous model [Fig: 2; OR=0.9187; 
95%CI=0.82-1.02; P<0.1289] showed that polymorphism, CYP3A5*3 6986 
A>G [rs776746] is not associated with cancer risk.    
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Introduction  
 Drug efficacy can be effected by the genetic differences of 
individuals or populations. Therefore, pharmacogenetics variations is 
considered as an important aspect in the diseases treatments and situation 
with personalized medication. In the view of such conditions, the efficacy 
and toxicity of the drugs can be enhanced in a person by focusing on the 
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phase I and phase II drug metabolism genes e.g. cytochrome P450 family 
[Desta et al., 2004: Hoskin., 2009].  
 There are four genes in the CYP3A family.  These genes are 
CYP3A4, CYP3A5, CYP3A7, and CYP3A43 that are well-known phase-I 
metabolism-related genes. These genes were traced in the 231-kb area of 
chromosome 7q21.1 [Goetz et al., 2001]. It is estimated that about 755 of the 
metabolic reaction are carried by CYP enzymes [Rae et al., 2012]. A huge 
number of investigations were carried out to find the consequence of genetic 
variation of CYP3A4 and CYP3A5. The CYP3A4 and CYP3A5 genes are 
most commonly involved in drug related reactions and activation of some 
drugs etc. [Regan et al., 2012]. Studies reported that CYP3A4 and CYP3A5 
accounts for 36% of activity of all CYP3A genes. The expression level of 
these genes is 30% occurring in liver and intestine [brooks et al., 2013: Mani 
et al., 1993: Iusuf et al., 2011]. 
 CYP3A5 expression associated with an intron 3 variation in liver. 
The CYP3A5*3 (CYP3A5 6986A>G) variant codes a different spliced 
mRNA with a premature terminator codon. More over wild type CYP3A5*1 
mRNA is more stable than CYP3A5*3 mRNA which is more unstable and 
quickly degraded [Kuehl et al., 2001]. 
 Earlier studies reported that, depending on the ethnicity the CYP 
enzymes indicated polymorphism across persons, with deficiencies going on 
in 1 to 30% of populations [Hesselink et al., 2003]..  
 
Material and methods 
 Literature search 
 In the present analysis Case control study Papers before March 2014 
were selected through Google advance search, PubMed, yahoo search, web 
of sciences. Papers were searched using the terms variants, polymorphisms, 
SNP or cancer risk and cyp3A5, polymorphism in cyp3A5 and enzyme 
superfamily p450 3A.  
 Inclusion and exclusion criteria 
 The criteria adopted for inclusion of the study papers were: (1) 
cyp3a5 polymorphism in population with cases and controls studies only (2) 
Confirmed cancer patients (3) case-control studies having sufficient 
genotypes of the required data. Exclusion criteria adopted in this meta-
analysis were: (1) studies without cases or controls (2) incomplete in data, 
(4) editorial articles letters, reviews and meta-analysis. 
 
Data extraction 
 Data from the included papers extracted with the following 
characteristics: the first author name, year of publication, country, ethnicity, 
number of cases, and number of controls, genotype frequencies i.e. AA, AG, 
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and GG. Data were extracted separately from Chinese, Caucasian, African 
Americans, Indians, Japanese, United Kingdom, Finnish and Asian.  
  
Statistical analysis  
 CYP3A5*1B (A>G) polymorphism and cancer risk was planned by 
odds ratios (ORs) with 95 %CI and was examined.  All analyses were 
measured using Comprehensive Meta-Analysis Version 2.0 (14 North Dean 
Street, Englewood, NJ 07631, USA) and online OR calculators.  
 
Results 
 In the present study an attempt was made to know find the 
association between polymorphism CYP3A5*3 6986 A>G [rs776746] under 
the heterozygous model to know whether it is associated with increased risk 
of cancer or not.  Following the inclusion criteria, eight studies were 
incorporated and 42 studies were excluded in this metaanalysis. The flow 
chart of study selection is shown in Fig. 1. The numbers of cancer cases and 
healthy controls were 4959 and 5176, respectively for evaluating the 
association between CYP3A5*3 6986 A>G [rs776746] polymorphism and 
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cancer risk. The publication years of included studies ranged from 2009 to 
2012. Overall, two of these studies were conducted in Indian populations and 
one in each of African American, Chinese, Japanese, UK, Finnish and Asian 
populations. There were two breast cancer studies, three prostate cancer 
studies, one on each of leukemia, CML colorectal and TB.  
 Association between CYP3A5*3 6986 A>G [rs776746] 
polymorphism and cancer risk summary is given in the Table 1. Genotypic 
data and frequency of A allele and G allele is given. Heterozygous model 
with OR, LCI, UCI, P value determined for each study. The heterogenecity 
model was significant [table: 1] in Chinese, Indian, Japanese and Asian 
population suffered in TB, CML, and breast cancers [OR: 0.50, 95 %CI: 
0.30-0.81, P<0.01; OR= 1.57, 95 %CI: 1.00-2.47, P<0.05; OR=0.69; 
95%CI=0.51-0.93; P<0.01; OR=0.61; 95%CI=0.42-0.89; P<0.01]    
 The overall statistics under heterozygous model [Fig: 2; OR=0.9187; 
95%CI=0.82-1.02; P<0.1289] showed that polymorphism, CYP3A5*3 6986 
A>G [rs776746] is not associated with cancer risk. Cumulative statistics of 
the studies included in the current meta-analysis given in the Fig: 1 suggest 
that GG vs. AG is not associated in the cancer risk [95%CI=0.82-1.02; p< 
0.1289] 
 Publication biases with Begger's funnel plot were achieved to weigh 
the publication biases of involved studies. No evidence of obvious 
unevenness was found under heterozygous model [Fig: 3]  
 
Table 1 CYP3A5*3 6986 A>G polymorphism and risk of disease. meta-analysis 
andcharacteristics of included studies 
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Fig 1 CYP3A5 polymorphism meta-analysis and cancer risk under model GG VS AG [Rare 
allele vs Heterozygous] 
 
Fig 2.  CYP3A5 polymorphism meta-analysis statistics for each study 
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Fig 3.  Begger's funnel plot for CYP3A5 polymorphism in meta-analysis 
 
Discussion 
 RNA splicing and enzymatic activity is affected by a polymorphism 
in the intronic region of CYP3A5 gene (CYP3A5*3; SNP rs776746) playing 
a defensive role for TB in china [Coto et al., 2007]. 
 Numerous  racial  groups  display  dissimilar  occurrences  of 
CYP450  allelic  alternates,  possibly  due  to  prehistoric  voyages of 
geologically divergent and remote anthropological clusters, shared with the 
effects of selective features, such as diet or illness [Lee et al., 2003]. Drug 
toxicity and response depends on the activity of inducers, dietary factors, and 
genetic factors that result of Inter-individual inconsistency in the catabolism 
of CYP3A substrates. The data available today showed that the activity of 
CYP3A5 gene is different in different ethnic groups is due to the 
polymorphisms in this genethat play a key role in drug clearance and 
response [Makeeva et al., 2008].  CYP3A5*1 is the single CYP3A5 variant 
that yields full-length CYP3A5 messenger RNA and showed the expression 
of CYP3A5 whereas the other collective CYP3A5 genetic variation in 
Caucasians, CYP3A5*3 6986 A>G [rs776746], expresses an abnormally 
spliced mRNA with a premature stop codon. Marked interethnic differences 
have been reported for the CYP3A5*3 allelic variant [Roy et al., 2005]. 
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 In the current metaanalysis no significant association was found 
between the single nucleotide polymorphism CYP3A5*3 and the risk of 
developing cancer in a rare allele vs heterozygous model (Fig: 2; 
OR=0.9187; 95%CI=0.82-1.02; P<0.1289) a previous study conducted on 
the Japanese population reported no significant association between 
CYP3A5*3 and the risk of developing breast cancer in a case control study 
conducted on Japanese Brazilians and non-Japanese Brazilians [Shimada et 
al., 2009]. The product of CYP3A5 also play an indirect role of inactivation 
of testosterone. That is the reason that CYP3A5*1 play protective activity of 
prostate cancer [Vaarala et al., 2008].  
 A 3/3 homozygous genotype and substantial raise  CYP3A5*3 allele  
frequency in CML population was detected which showed  that the loss of 
CYP3A5 expression linked with  altered allele might be accountable for the 
buildup  of endogenous steroids or xenobiotics in various tissue which might 
bring genotoxicity that consult the threat for disease vulnerability [21Bethke 
et al., 2007]. Further, previous studies also reported the same frequencies of 
CYP3A5*3 variant in together the leukemia and controls [Liu et al., 2002: 
Balanco et al., 2002: Aplenc et al., 2003: Bajpai et al., 2010] failed to detect 
significant relationship between CYP3A5 SNP and illness of severe CML 
patients, but the appearance of CYP3A5 in serious CML patients was strictly 
linked with the therapeutic result and diagnosis [Shen et al., 2008].  An 
earlier study published about the prevalence colorectal cancer in Bulgarian 
population showed no significant association between CYP3A5*3 6986 
A>G [rs776746] variations and incidence this cancer [Petrova et al., 2007]. 
Similarly no significant association was found between the Finnish 
population and CYP3A5*1 or *3 variants, and risk of prostate cancer 
[Markku et al., 2008]. 
 Our metaanalysis has several limitations. The studies included in this 
analysis and Cases and controls are also not too much. Further detailed 
information is needed to find the association between CYP3A5*3 SNP 
rs776746 and cancers risk and our result might be limited.  
 In conclusion no significant association was found between 
CYP3A5*3 SNP rs776746 and the risk of developing different types of 
cancers. 
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